@article{10902/27778,
year = {2023},
url = {https://hdl.handle.net/10902/27778},
abstract = {ackground & Aims
There is conflicting evidence regarding the prevalence of and risk factors for metabolic-associated fatty liver disease (MAFLD) in patients with inflammatory bowel disease (IBD). We aimed to determine MAFLD prevalence and risk factors in IBD patients.
Methods
Cross-sectional, case-control study included all consecutive IBD patients treated at 2 different university hospitals. Controls were subjects randomly selected from the general population and matched by age, sex, type 2 diabetes status, and body mass index in a 1:2 ratio. MAFLD was confirmed by controlled attenuation parameter. Liver biopsies were collected when MAFLD with significant liver fibrosis was suspected. In addition, age- and fibrosis stage-paired non-IBD patients with biopsy-proven MAFLD served as a secondary control group.
Results
Eight hundred thirty-one IBD patients and 1718 controls were included. The prevalence of MAFLD and advanced liver fibrosis (transient elastography ≥9.7 kPa) was 42.00% and 9.50%, respectively, in IBD patients and 32.77% and 2.31%, respectively, in the general population (P < .001). A diagnosis of IBD was an independent predictor of MAFLD (adjusted odds ratio, 1.99; P < .001) and an independent risk factor for advanced liver fibrosis (adjusted odds ratio, 5.55; P < .001). Liver biopsies were obtained from 40 IBD patients; MAFLD was confirmed in all cases, and fibrosis of any degree was confirmed in 25 of 40 cases (62.5%). Body mass index and type 2 diabetes prevalence were significantly lower in IBD-MAFLD patients than in severity-paired patients with biopsy-proven MAFLD.
Conclusions
MAFLD and liver fibrosis are particularly prevalent in IBD patients, regardless of the influence of classic metabolic risk factors.},
organization = {Acknowledgements: The authors report funding support from the Spanish Instituto de Salud Carlos III-FEDER Grant (FIS - PI18/01304) related to this manuscript.},
publisher = {Elsevier},
publisher = {Clinical Gastroenterology and Hepatology, 2023, 
21(2), 406-414.e7},
title = {Increased risk of MAFLD and liver fibrosis in inflammatory bowel disease independent of classic metabolic risk factors},
author = {Rodríguez-Duque, Juan Carlos and Calleja, José Luis and Iruzubieta Coz, Paula and Hernández-Conde, Marta and Rivas-Rivas, Coral and Vera, María Isabel and García, María José and Pascual, Marta and Castro, Beatriz and García Blanco, Agustín and García Nieto, Enrique and Curiel Del Olmo, Soraya and Cagigal Cobo, María Luisa and López-Montejo, Lorena and Fernández-Lamas, Tatiana and Rasines, Laura and Fortea Ormaechea, José Ignacio and Vaqué Díez, José Pedro and Frías, Yza and Rivero Tirado, Montserrat and Arias Loste, María Teresa and Crespo García, Javier},
}